Keybank National Association Esperion Therapeutics, Inc. Transaction History

Keybank National Association

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 30, 2019	SELL	$36.99 - $59.11 $218,351 - $348,926	-5,903 Closed	0 $0
Q3 2018 Nov 08, 2018	SELL	$40.74 - $51.41 $71,702 - $90,481	-1,760 Reduced 22.97%	5,903 $262,000
Q2 2018 Aug 08, 2018	BUY	$36.2 - $76.4 $137,089 - $289,326	3,787 Added 97.7%	7,663 $300,000
Q1 2018 May 15, 2018	SELL	$65.94 - $80.76 $73,523 - $90,047	-1,115 Reduced 22.34%	3,876 $280,000
Q3 2017 Nov 02, 2017	SELL	$43.8 - $52.77 $81,599 - $98,310	-1,863 Reduced 27.18%	4,991 $250,000
Q2 2017 May 14, 2018	SELL	N/A	-334 Reduced 4.65%	6,854 $317,000
Q1 2017 May 14, 2018	SELL	N/A	-5,503 Reduced 43.36%	7,188 $254,000
Q4 2016 May 14, 2018	BUY	N/A	12,691	12,691 $159,000

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $171M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

Stay updated on Keybank National Association with notifications on news.